Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

8.380 +0.010 (+0.12%)
Streaming Delayed Price Updated: 10:12 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vir Biotechnology Inc

< Previous 1 2 Next >
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimab 
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – 
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
From Vir Biotechnology, Inc.
Via GlobeNewswire
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
From Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.